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Abstract
Background—Hepatitis B (HepB) vaccination is the most effective measure to prevent HBV 
infection. Routine HepB vaccination was recommended for infants in 1991 and catch-up 
vaccination has been recommended for adolescents since in 1995. The purpose of this study is to 
assess HepB vaccination among adolescents 13–17 years.
Methods—The 2006–2012 NIS-Teen were analyzed. Vaccination trends and coverage by birth 
cohort among adolescents were evaluated. Multivariable logistic regression and predictive 
marginal models are used to identify factors independently associated with HepB vaccination.
Results—HepB vaccination coverage increased from 81.3% in 2006 to 92.8% in 2012. Coverage 
varied by birth cohort and 79–83% received vaccination before 2 years of age for those who were 
born during 1995 and 1999. Among those who had not received vaccination by 11 years of age, 
for the 1993–1995 birth cohorts, 9–15% were vaccinated during ages 11–12 years, and 27–37% 
had been vaccinated through age 16 years. Coverage among adolescents 13–17 years in 2012 
ranged by state from 84.4% in West Virginia to 98.7% in Florida (median 93.3%). Characteristics 
independently associated with a higher likelihood of HepB vaccination included living more than 
5 times above poverty level, living in Northeastern or Southern region of the United States, and 
having a mixed facility as their vaccination provider. Those with a hospital listed as their 
vaccination provider and those who did not have a well-child visit at age 11–12 years were 
independently associated with a lower likelihood of HepB vaccination.
Conclusions—Efforts focused on groups with lower coverage may reduce disparities in 
coverage and prevent hepatitis B infection. Parents and providers should routinely review 
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adolescent immunizations. Routine reminder/recall, expanded access in health care settings, and 
standing order programs should be incorporated into routine clinical care of adolescents.
Keywords
Hepatitis B vaccine; Vaccination; Coverage; Adolescent vaccination; The National Immunization 
Survey-Teen (NIS-Teen)
1. Introduction
Hepatitis B virus (HBV) is transmitted by percutaneous or mucosal exposure to the blood or 
body fluids of an infected person. Among infants who acquire HBV infection at birth, as 
many as 90% remain chronically infected, whereas approximately 30–50% of children 
infected at age 1–5 years and 5% of healthy adults remain chronically infected [1,2]. An 
estimated 800,000–1.4 million persons in the United States live with chronic HBV infection; 
many are not aware of their infection [1–3].
Preventing HBV infection through vaccination is the most effective way to reduce HBV-
related, life-long complications, reduce the reservoir of persons with chronic infection, and 
thereby eliminate HBV transmission. Hepatitis B (HepB) vaccines have proved safe, and 
approximately 95% effective at preventing HBV infection [1,2,4,5]. Protection induced by 
HepB vaccines has been monitored among populations for more than 22 years and remains 
high [6].
In 1981, HepB vaccine was first approved for use in the United States. In 1982, the Advisory 
Committee on Immunization Practices (ACIP) recommended HepB vaccination for adults at 
increased risk for HBV infection [7]. In 1991, recognizing the difficulty of vaccinating high-
risk adults and the substantial burden of HBV-related infections acquired from childhood 
infection (an estimated 30–50%) [1,2,8,9], the ACIP recommended children receive a HepB 
vaccine series starting in infancy [8]. It is important for children to receive HepB vaccination 
starting in infancy since sexual activity and risk behaviors may start in adolescence. 
Additionally, since adolescents and adults with risk behaviors may be difficult to identify, 
opportunities to offer vaccination are missed [8]. In 1995, ACIP recommended routine 
vaccination for all previously unvaccinated adolescents 11–12 years [10], and in 1999, the 
recommendations were broadened to include all previously unvaccinated children and 
adolescents 0–18 years.
Ensuring adolescents are vaccinated to protect against HBV infection has been an important 
public health concern since 1995 [11]. School immunization laws were modified in many 
states to reflect the new recommendations [12] and HepB vaccine coverage has been 
increasing among adolescents [13–15]. To reach the goal of eliminating HBV transmission 
in the United States and reduce the hepatitis B disease burden, high rates of protection 
among adolescents must be achieved for each adolescent cohort [1,2,16,17]. To determine 
the status of HepB coverage among adolescents 13–17 years in the United States, we used 
data from the 2006–2012 National Immunization Survey-Teen (NIS-Teen). We also sought 
to identify factors independently associated with higher or lower vaccination coverage, and 
evaluate the extent of adolescent HepB vaccination catch-up.
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2. Methods
The National Immunization Survey-Teen (NIS-Teen) was analyzed in 2014. The NIS-Teen is 
a national, random-digit-dialed (RDD) telephone survey sponsored by the Centers for 
Disease Control and Prevention (CDC). The objective of the NIS-Teen is to provide timely, 
detailed information regarding vaccination among adolescents 13–17 years for vaccines 
recommended by the ACIP, including those given during childhood and during adolescence 
as catch up. The NIS-Teen is a two-phase survey. During the first phase, a telephone 
household interview is conducted to identify households with age-eligible adolescents. 
Initially, NIS-Teen only used a landline sample. However, beginning in 2011, the survey 
included landline and cellular telephone households [18,19]. After completing the household 
interview, consent is requested to contact the vaccination provider(s) to collect vaccination 
records.
The second phase of NIS-Teen is a Provider Record Check (PRC). An Immunization History 
Questionnaire is mailed to the vaccination provider to complete or to attach a copy of the 
vaccination record of the adolescent and mail back to the data collector. The questionnaire 
includes documented vaccinations for the adolescent, whether the adolescent had a well-
child visit or check-up at the practice during ages 11–12 years, and selected characteristics 
of the provider and practice.
In 2012, the Council of American Survey Research Organizations (CASRO) landline 
response rate was 55.1%. A total of 14,133 adolescents with provider-reported vaccination 
records were included, representing 62% of all adolescents from the landline sample with 
completed household interviews. The cellular-telephone sample CASRO response rate was 
23.6%. A total of 5066 adolescents with provider-reported vaccination records were 
included, representing 56.4% of all adolescents from the cellular-telephone sample with 
completed household interviews. The overall sample size (landline and cellphone sample) 
was 19,199 [14]. Poverty status was defined using 2012 poverty thresholds published by the 
U.S. Census Bureau with below poverty defined as a total family income of <$23,492 for a 
family of four.
In the United States, there were two monovalent HepB vaccines for pediatric use (through 
age 18 years) and one combination vaccine available to adolescents who were 13–17 years 
in 2012. We used fully immunized as the outcome measure of HepB vaccination. Being fully 
immunized with HepB vaccine was defined as receipt of ≥3 doses of 0.5 ml of [1]: Engerix-
B®, Recombivax HB®, or Comvax® [20], combinations of these three vaccines, or [2]: 
receipt of ≥2 doses of 1.0 ml of Recombivax HB® approved in 2000 as a two dose series for 
adolescents 11–15 years. Comvax® might have been available for infants born from 1996 to 
1999, who are now adolescents 13–16 years. We assessed the association of the outcome 
measure with demographic and access to care characteristics. To assess missed 
opportunities, we evaluated the percentage of those who had not been fully vaccinated 
against hepatitis B by 11 years of age who had a vaccination visit, defined as those who had 
received a vaccination other than HepB during the period from their 11th year birthday 
through their age at interview (13–17 years).
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SUDAAN (Software for the statistical analysis of complex sampling data, Research Triangle 
Institute, Research Triangle Park, NC) was used to calculate point estimates and 95% 
confidence intervals (CIs). Weighting is adjusted to minimize non-response bias (e.g., to 
compensate for the non-coverage of teens in non-telephone households, a post-stratification 
adjustment is done based on whether the teen’s household experienced an interruption in 
telephone service). T-tests were used to examine associations with the significance level set 
at α< 0.05. Using combined data from 2006 to 2012, Kaplan–Meier survival analysis was 
conducted to estimate, by birth cohort, the cumulative vaccination coverage by age overall, 
and among those who had not been vaccinated before their 11th year birthday (adolescent 
catch-up vaccination). To assess the independent effects of demographic and access-to-care 
variables on HepB vaccination, we conducted multivariable logistic regression and 
predictive marginal models which yielded adjusted prevalence difference (PD). The NIS-
Teen was approved by the Centers for Disease Control and Prevention, National Center for 
Health Statistics Research Ethics Review Board.
3. Results
A total of 19,199 adolescents 13–17 years with adequate provider data from the 2012 NIS-
Teen were included in the study. Table 1 shows the demographic characteristics of the 2012 
sample.
Among adolescents 13–17 years, overall HepB coverage was 92.8% (95% confidence 
interval (CI = 92.1–93.5%) in 2012 (Table 2). Vaccination coverage was similar by age 
group and sex. Hispanics had significantly lower coverage (91.1%) compared to non-
Hispanic whites (93.7%). Adolescents with a mother who had more than a college degree 
(94.9%) were significantly more likely to receive HepB vaccination than those with a mother 
who had less than high school education (90.8%) (p < 0.05). HepB vaccination coverage was 
significantly higher among adolescents living in a household with 3–5 times above poverty 
level (93.6%) (p = 0.02) or more than 5 times above poverty level (95.9%) compared with 
those living below the poverty level (91.2%) (p < 0.01) (Table 2).
Adolescents with military medical insurance (85.0%) were significantly less likely to receive 
HepB vaccination than those with private medical insurance (94.2%) (p = 0.03). HepB 
vaccination coverage was significantly higher among those with one physician contact 
(94.1%) compared to those who had no physician contacts in the past year (91.2%) (p = 
0.01). Adolescents who did not have a well-child visit at ages 11–12 years (based on 
provider reported data) were significantly less likely to obtain vaccination (92.2%) than 
those who had a visit (96.0%) (p < 0.01) (Table 2).
HepB vaccination coverage varied by region of residence; it was significantly higher among 
persons who lived in the Northeast (95.3%) and the South (93.7%) than those who lived in 
the West (90.9%) (p < 0.01, p = 0.01, respectively). Adolescents who received vaccinations 
at facilities such as hospital and “other” facilities (coverage was 86.5%, and 73.8%, 
respectively) were significantly less likely to be vaccinated with HepB than those who 
received vaccinations at private facilities (93.7%) (p < 0.01). Adolescents who received 
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vaccinations at mixed facilities (95.8%) were significantly more likely to be vaccinated with 
HepB than those who received vaccinations at private facilities (93.7%) (p < 0.01) (Table 2).
Multivariable logistic regression modeling and predictive marginal analysis were conducted 
using the 2012 data to identify factors independently associated with HepB vaccination 
among adolescents 13–17 years (Table 2). Characteristics independently associated with a 
higher likelihood of HepB vaccination included: living more than 5 times above the poverty 
level compared with living below the poverty level (PD = 3.2), living in the Northeastern 
(PD = 3.4) or the Southern region (PD = 2.3) of the United States compared with those 
living in the West, and having a mixed facility as their vaccination provider compared with a 
private facility (PD = 3.7). Adolescents with a hospital (PD = −4.6) or “other” facility (PD = 
−10.4) listed as their vaccination provider compared with a private facility and those who 
did not have a well-child visit at ages 11–12 years (PD = −3.3) compared with those who 
had a well-child visit at ages 11–12 years were independently associated with a lower 
likelihood of HepB vaccination (Table 2). Race/ethnicity, mother’s educational level, and 
number of physician contacts within the past year were significant in the bi-variable analysis 
but were no longer significant in the multivariable model.
Overall, vaccination coverage by state ranged from 84.4% in West Virginia to 98.7% in 
Florida, with a median across all states of 93.3% (Table 3). Coverage before 11 years of age 
by state ranged from 81.1% in West Virginia to 96.9% in New Hampshire, with a median of 
91.3%. Catch-up vaccination proportion after 11 years of age by state ranged from 0.0% in 
Kentucky and Ohio to 78.3% in Florida, with a median of 24.6% (Table 3). The proportion 
of adolescents not fully vaccinated before age 11 years who were subsequently vaccinated 
ranged from 0.0% to 78.2% (median 24.6%). The median catch-up vaccination proportion at 
or after 11 years of age among states with HepB vaccination middle school requirements 
was 22.5% compared to 19.4% among states without HepB vaccination middle school 
requirements.
Tables 4–5 and Figs. 1–3 are based on the combined 2006–12 data. Sample sizes for 2006, 
2007, 2008, 2009, 2010, and 2011 were 1882, 2947, 17,835, 20,066, 19,257, 23,564, 
respectively. Among adolescents born during 1995–1999, 79–83% had been fully vaccinated 
before two years of age, 85–89% had been fully vaccinated before five years of age, and 90–
93% had been fully vaccinated before 11 years of age (Table 4). Among those born during 
1993–1995 who had not been vaccinated before 11 years of age, adolescent catch-up 
vaccination coverage was 9–15% during ages 11–12 years, and increased for each birth 
cohort for later ages, reaching 27–37% before age 17 years. For all ages of receipt, 
adolescent catch-up coverage has declined from the earliest to the most recent birth cohorts. 
For the most recent cohort followed to age 17 years (born in 1995, or turned 11 in 2006), 
catch-up coverage was 27% (Table 5). Adolescent catch-up coverage during ages 11–12 
years declined from 48% among those born in 1989 to 29% among those born in 1992, and 
ranged from 9 to 15% among those born during 1993–1999 (Fig. 1, Table 5).
Overall, HepB vaccination coverage among adolescents aged 13–17 years significantly 
increased from 81.3% in 2006 to 92.8% in 2012 (test for trend, p < 0.05) (Fig. 2), with an 
average 2.0 percentage point increase annually. Coverage among non-Hispanic whites 
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significantly increased from 82.4% in 2006 to 93.7% in 2012 (test for trend, p < 0.05), and 
coverage among non-Hispanic blacks significantly increased from 74.8% in 2006 to 92.5% 
in 2012 (test for trend, p < 0.05) (Fig. 2). HepB vaccination coverage did not change 
significantly between 2006 and 2012 for Hispanics and Asians (Fig. 2). Numbers were too 
small to examine trends for American Indians/Alaskan Natives. Coverage for adolescents 
13–15 years significantly increased from 84.3% in 2006 to 93.3% in 2012 (test for trend, p < 
0.05), and coverage for adolescents 16–17 years increased from 76.4% in 2006 to 92.1% in 
2012 (test for trend, p < 0.05) (Fig. 3).
Among those not fully vaccinated against HepB vaccination in the 2012 NIS-Teen sample, 
59.5% did not receive any dose, 15.4% received 1 dose, and 25.1% received 2 doses of 
HepB vaccination. Among those not fully vaccinated against HepB vaccination, overall, 
78.0% had at least one vaccination visit (received a vaccination other than HepB), and 
22.0% did not have any vaccination visits. Among those who did not receive any dose of 
HepB, overall, 85.2% had at least one vaccination visit. Among those who received one dose 
of HepB, overall, 56.7% had at least one vaccination visit. Among those who received two 
doses of HepB, overall, 74.3% had at least one vaccination visit.
4. Discussion
Our study using the NIS-Teen showed that 93% of adolescents 13–17 years in the United 
States in 2012 were fully vaccinated against hepatitis B, an increase of 12 percentage points 
compared to 2006 [13,15]. Among adolescents aged 13–17 years in 2012 (born 1995–1999), 
the percentage with completed HepB vaccination was 79–83% before age two years, 85–
89% before five years of age, and 90–93% before age 11 years. Thus, a large proportion of 
the high HepB vaccination coverage among adolescents was likely due to ACIP 
recommendations for universal infant vaccination in 1991 and well-established childhood 
vaccination programs, decreasing the need for vaccination later in childhood or adolescence 
[8]. HepB vaccination “catch-up” recommendations in 1995 and 1999 contributed to the 
resulting HepB coverage above 90% for cohorts born from 1996 to 1999 [10,12,15]. Among 
adolescents who had not received the full HepB vaccination by 11 years of age, the 
proportion who received catch-up HepB vaccination during ages 11–12 years was low (9–
15%) for the most recently measured cohorts (those turning age 11 years during 2004–
2010). HepB catch-up vaccination coverage increased with age but remained low (27–37%) 
by age 17 years for the most recent cohorts followed to age 17 (those turning 11 years 
during 2004–2006).
Gaps may not be apparent when coverage is at a high level. Despite the substantial gains in 
HepB vaccination, 7.2% of adolescents 13–17 years had not received a complete HepB 
vaccination series in 2012. Studies have reported racial/ethnic differences among adult 
vaccination in the United States [21–23]. However, recent studies indicate that racial/ethnic 
disparities among childhood vaccination have been significantly reduced or not observed for 
some vaccinations [24,25]. Among adolescents 13–17 years, differences in HepB 
vaccination coverage among Hispanics and non-Hispanic whites were no longer significant 
after controlling for demographic characteristics and access to care variables in the 
multivariable model. Middle-school mandates may contribute to the reduced racial and 
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ethnic disparities in HepB vaccination coverage [15,26]. Additionally, the Vaccine for 
Children (VFC) program, which provides vaccines at no cost to eligible children through the 
age of 18 years if families might not otherwise be able to afford vaccines, and enrollment in 
the State Children’s Health Insurance Plan may also help reduce racial and ethnic disparities 
in receipt of preventive services that include vaccination [15,27].
This study indicated disparities in HepB vaccination coverage based on health insurance 
status in the bi-variable analysis. However, health insurance status was not independently 
associated with HepB vaccination when controlling for demographic and access to care 
variables in the multivariable analysis. Our study and other previous studies estimated that 
approximately 6–7% of adolescents were uninsured [15,28] and these children were at 
greater risk of not being vaccinated as recommended [15,28]. Our finding of similar HepB 
vaccination coverage by insurance status may be due to the contribution of the VFC program 
and CDC’s Vaccines for Children and Section 317 Cooperative Agreement [29–32]. The 
Vaccines for Children and CDC’s Section 317 Cooperative Agreement provides federal 
funds to state and local health departments to support immunization infrastructure to ensure 
access to vaccination services. These programs may help improve vaccination coverage 
among uninsured adolescent populations. Federal, state, and local partners should continue 
to build support for adolescent vaccination and address pockets of need for uninsured 
adolescents. Additionally, military health insurance is associated with lower vaccination 
rates through this association did not remain in the multivariable analysis. The population 
may be more transient which may have implications for more preventive services including 
vaccination. Further study is needed to look into reasons for gaps in HepB vaccination 
between adolescents with military health insurance and other health types of health 
insurances.
HepB vaccination coverage among adolescents 13–17 years varied by state and region of 
residence. Factors that might have contributed to the variability in vaccination coverage 
include differences in the way state vaccination programs are implemented, in medical-care 
delivery infrastructure; in the effectiveness of interventions being implemented by states 
other stakeholders; in population attitudes toward vaccinations; in immunization resources; 
in reimbursements for vaccines and vaccine administration; and in state and local policies 
(e.g., laws requiring vaccines for school entry) [33–40].
We found that about 7% of adolescents 13–17 years in 2012 had not received the complete 
HepB vaccination series, placing them at risk for infection and cancer and highlighting the 
need for continued provision of catch up vaccinations. However, our study showed that 
adolescent HepB vaccination catch-up coverage during ages 11–12 years decreased four-fold 
from 48% for those born in 1989 to only 12% for those born in 1999. This may reflect a 
decreasing emphasis by clinicians on assessing HepB vaccination status over time as more 
adolescents were vaccinated during infancy or early childhood, and many adolescents had 
opportunities to receive HepB vaccination when receiving other vaccinations. The ACIP and 
other partner organizations, including the American Academy of Pediatrics, American 
Medical Association, and Society for Adolescent Medicine, recommend a well-child visit 
for children ages 11–12 years to receive recommended vaccinations and indicated preventive 
services such as vaccinations required to attend middle school [15,26,41]. Our study showed 
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that the majority of adolescents not fully vaccinated against HepB had at least one visit 
where other vaccinations were provided. Approximately 80% of adolescents who did not 
receive any doses of HepB vaccine could have received at least one dose if the opportunity 
to provide a vaccination was not missed. Approximately 63% of adolescents with only one 
dose of HepB vaccine could have received the second dose if the opportunity to provide a 
vaccination was not missed. Using Immunization Information Systems (IIS) and client 
reminder and recall systems with standing orders, provider reminders for vaccinations or 
provider assessment/feedback have been shown to be effective strategies to assist 
vaccinations providers to routinely provide HepB vaccination to their patients, ensuring 
fewer missed opportunities and higher vaccination coverage [42].
The findings in this study are subject to limitations. First, household response rate is 55.1%, 
and some bias may remain after weighting adjustments designed to minimize non-response 
bias [43]. However, the basic demographic characteristics by age, gender, and race/ethnicity 
from the 2012 National Immunization Survey-Teen were similar to those observed in the 
child core data of the 2012 National Health Interview Survey (CDC unpublished data). 
Second, provider-confirmed vaccination histories might not include all vaccinations 
received, such as a HepB vaccination received in a birth hospital or HepB vaccinations 
provided by someone other than the vaccination provider listed by the parent or guardian. 
This could result in underestimated vaccination coverage as measured by the NIS-Teen. 
Third, vaccination estimates from landline only (2007–2010) and dual sampling frames 
(2011–2012) might not be comparable. However, prior methodological assessment suggests 
that the addition of cellular telephone numbers beginning in 2011 should have had limited 
effects on annual national coverage estimates [14]. Fourth, NIS-Teen excluded persons 
without telephones and subsequently may result in possible selection bias. Finally, there may 
be some associations between insurance status, socioeconomic status and facility type where 
vaccines are received and further study or investigation is needed to assess the association 
and its impact on vaccination.
HepB vaccination coverage among adolescents is now at a high level; however, additional 
improvement is feasible and opportunities for adolescent catch-up vaccination efforts should 
not be missed. Increasing use of HepB vaccine has resulted in decreased cases of acute HBV 
infections among persons aged ≤19 years (incidences among persons aged ≤19 years were 
0.61 in 2000, and 0.03 in 2012, respectively, per 100,000 population) [17]. NIS results 
indicate HepB vaccination is stable around 90%. But by 2012, about 7% of adolescents 13–
17 years had not received the complete HepB vaccination series and among adolescents who 
had not received the full HepB vaccination by 11 years of age, the proportion who received 
catch-up HepB vaccination during ages 11–12 years was low (9–15%) indicating catch-up as 
part of school entry may not reach all those unvaccinated as infants. Even though 
vaccination at younger ages is recommended and preferred to reduce serious complications 
from infection, catch-up vaccination is particularly important since catch up vaccination can 
provide protections and may be the last opportunity to provide protection before risk 
behaviors are likely to be initiated [8,10]. Eligible adolescents can receive recommended 
vaccines at no cost through Vaccines for Children (VFC) program. Providers, parents, and 
adolescents should use every health-care visit, whether for health problems, well-checks, or 
physicals for sports, school, or camp, as an opportunity to review adolescents’ vaccination 
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histories and ensure that every adolescent is fully vaccinated with HepB vaccine and other 
recommended vaccines [41,44].
References
1. Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to 
eliminate transmission of hepatitis B virus infection in the United States: recommendations of the 
Advisory Committee on Immunization Practices (ACIP). MMWR. 2006; 55(RR-16):1–25.
2. Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to 
eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the 
Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of infants, children, 
and adolescents. MMWR Recomm Rep. 2005; 54(RR16):1–23.
3. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, et al. The prevalence 
of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010 Jul; 
202(2):192–201. [PubMed: 20533878] 
4. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunization in newborn infants 
of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. Br Med J. 
2006; 332:328–36. [PubMed: 16443611] 
5. Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn 
infants: a review. Vaccine. 2013; 31:18–21.
6. Schillie S, Murphy TV, Sawyer M, Ly K, Hughes E, Jiles R, et al. CDC guidance for evaluating 
health-care personnel for hepatitis B virus protection and for administering post-exposure 
management. MMWR. 2013; 62(RR-10):1–19.
7. Centers for Disease Control and Prevention (CDC). Inactivated hepatitis B vaccine. MMWR. 1982; 
31:317–8. [PubMed: 6811846] 
8. Centers for Disease Control and Prevention (CDC). Hepatitis B virus: a comprehensive strategy for 
eliminating transmission in the United States through universal childhood vaccination. MMWR. 
1991; 40(RR-13)
9. Centers for Disease Control and Prevention (CDC). [accessed 09.01.14] The ABCs of hepatitis fact 
sheet. 2010. Publication No. 21-1076. Available at: http://www.cdc.gov/hepatitis/Resources/
Professionals/PDFs/ABCTable.pdf
10. Centers for Disease Control and Prevention (CDC). Update: recommendations to prevent hepatitis 
B virus transmission – United States. MMWR. 1995; 44:574–5. [PubMed: 7616955] 
11. Lawrence MH, Goldstein MA. Hepatitis B immunization in adolescents. J Adolesc Health. 1995; 
17:234–43. [PubMed: 8580124] 
12. Centers for Disease Control and Prevention (CDC). Update: recommendations to prevent hepatitis 
B virus transmission – United States. MMWR. 1999; 48:33–4. [PubMed: 9933127] 
13. Centers for Disease Control and Prevention (CDC). National vaccination coverage among 
adolescents aged 13–17 years – United States, 2006. MMWR. 2007; 56:885–6. [PubMed: 
17728694] 
14. Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among 
adolescents aged 13–17 years – United States, 2012. MMWR. 2013; 62(34):685–93. [PubMed: 
23985496] 
15. Jain N, Hennessey K. Hepatitis B vaccination coverage among U.S. adolescents, National 
Immunization Survey-Teen, 2006. J Adolesc Health. 2009 Jun; 44(6):561–7. [PubMed: 19465320] 
16. Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis – United 
States, 2007. MMWR. 2009; 57(SS-03):1–27.
17. Centers for Disease Control and Prevention (CDC). [accessed 09.01.14] Viral hepatitis statistics & 
surveillance. Available at: http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/
Commentary.htm#hepB
18. Jain N, Singleton JA, Montgomery M, Skalland B. Determining accurate vaccination coverage 
rates for adolescents: an overview of the methodology used in the National Immunization Survey-
Teen 2006. Public Health Rep. 2009; 124(5):642–51. [PubMed: 19753942] 
Lu et al. Page 9
Vaccine. Author manuscript; available in PMC 2018 February 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
19. Centers for Disease Control and Prevention (CDC). [accessed 09.06.14] National Immunization 
Survey-Teen. Available at: ftp://ftp.cdc.gov/pub/HealthStatistics/NCHS/
DatasetDocumentation/NIS/NISTEENPUF12DUG.pdf
20. Centers for Disease Control and Prevention (CDC). Notice to readers. FDA approval for infants of 
a Haemophilus influenzae type b conjugate and hepatitis B (recombinant) combined vaccine. 
MMWR. 1997; 46:107–9. [PubMed: 9045037] 
21. Lu PJ, Singleton JA, Euler GL, Williams WW, Bridges CB. Seasonal influenza vaccination of adult 
populations, U.S., 2005–2011. Am J Epidemiol. 2013 Nov; 178(9):1478–87. [PubMed: 24008912] 
22. Lu PJ, Santibanez TA, Williams WW, Zhang J, Ding H, Bryan L, et al. Surveillance of influenza 
vaccination coverage – United States, 2007–08 through 2011–12 influenza seasons. MMWR 
Surveill Summ. 2013 Oct; 62(Suppl 4):1–29.
23. Centers for Disease Control and Prevention (CDC). Non-influenza vaccination coverage among 
adults – United States, 2011. MMWR. 2013; 62(04):66–72. [PubMed: 23364272] 
24. Wooten KG, Luman ET, Barker LE. Socioeconomic factors and persistent racial disparities in 
childhood vaccination. Am J Health Behav. 2007 Jul-Aug;31(4):434–45. [PubMed: 17511578] 
25. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination 
coverage among children aged 19–35 months – United States, 2012. MMWR. 2013; 62(36):733–
40. [PubMed: 24025754] 
26. Enger KS, Stokley S. Meningococcal conjugate vaccine uptake, measured by Michigan’s 
immunization registry. J Adolesc Health. 2007; 40:398–404. [PubMed: 17448396] 
27. Sanofi Pasteur. [accessed 16.01.14] Statement regarding the availability of Menactra vaccine. 2005. 
Available at: http://www.acha.org/sanofipasteur_7-19-05.pdf
28. Dorell CG, Yankey D, Byrd KK, Murphy TV. Hepatitis. A vaccination coverage among 
adolescents in the United States. Pediatrics. 2012 Feb; 129(2):213–21. [PubMed: 22271690] 
29. Centers for Disease Control and Prevention (CDC). [accessed 13.01.14] Vaccines for children 
program. Available at: http://www.cdc.gov/vaccines/programs/vfc/default.htm
30. Ching PL. Evaluating accountability in the Vaccines for Children program: protecting a federal 
investment. Public Health Rep. 2007 Nov-Dec;122(6):718–24. [PubMed: 18051664] 
31. Dorell CG, Yankey D, Santibanez TA, Markowitz LE. Human papillomavirus vaccination series 
initiation and completion, 2008–2009. Pediatrics. 2011 Nov; 128(5):830–9. [PubMed: 22007006] 
32. Centers for Disease Control and Prevention (CDC). [accessed 11.06.14] Immunization Program 
Operations Manual (IPOM) (Vaccines for Children and Section 317 Cooperative Agreement). 
Available at: http://www.cdc.gov/vaccines/imz-managers/guides-pubs/ipom/basics.html
33. National, state, and local area vaccination coverage among adolescents aged 13–17 years – United 
States, 2009. MMWR. 2010; 59(32):1018–23. [PubMed: 20724968] 
34. Lee GM, Santoli JM, Hannan C, Messonnier ML, Sabin JE, Rusinak D, et al. Gaps in vaccine 
financing for underinsured children in the United States. JAMA. 2007; 298:638–43. [PubMed: 
17684186] 
35. Freed GL, Cowan AE, Clark SJ. Primary care physician perspectives on reimbursement for 
childhood immunizations. Pediatrics. 2008; 122:1319–24. [PubMed: 19047252] 
36. Rodewald, LE. Timing of the implementation of new vaccines in the VFC program. Presented at: 
Centers for Disease Control and Prevention (US)/Agency for Toxic Substances and Disease 
Registry, Tribal Consultation Advisory Committee meeting; 2009; 
37. Pruitt SL, Schootman M. Geographic disparity, area poverty, and human papillomavirus 
vaccination. Am J Prev Med. 2010; 38:525–33. [PubMed: 20409501] 
38. Freed GL, Cowan AE, Gregory S, Clark SJ. Variation in provider vaccine purchase prices and 
payer reimbursement. Pediatrics. 2008; 122:1325–31. [PubMed: 19047253] 
39. Lindley MC, Smith PJ, Rodewald LE. Vaccination coverage among U.S. adolescents aged 13–17 
years eligible for the Vaccines for Children program, 2009. Public Health Rep. 2011 Jul-Aug;
126(Suppl 2):124–34.
40. Centers for Disease Control and Prevention (CDC). [accessed 13.01.14] Hepatitis B prevention 
mandates for children in day care and schools. Available at: http://www.immunize.org/pdfs/
hepb.pdf
Lu et al. Page 10
Vaccine. Author manuscript; available in PMC 2018 February 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
41. Centers for Disease Control and Prevention (CDC). Recommended immunization schedules for 
persons aged 0–18 years – United States, 2013. MMWR. 2013; 62(Suppl 1):1–19.
42. Centers for Disease Control and Prevention (CDC). The community guide. Atlanta, GA: 2013. The 
guide to community preventive services. Available at http://www.thecommunityguide.org/
index.html [accessed 13.01.14]
43. Dolson, D. [accessed 16.07.14] Errors of non-observation: dwelling nonresponse and coverage 
error in traditional censuses. Available at: http://www.amstat.org/sections/srms/proceedings/
44. Centers for Disease Control and Prevention (CDC). General recommendations on immunization: 
recommendations of the Advisory Committee on Immunization Practices. MMWR. 2011; 
60(RR-2)
Lu et al. Page 11
Vaccine. Author manuscript; available in PMC 2018 February 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1. 
Proportion of adolescents receiving hepatitis B vaccination at 11–12 years of age among 
those who had not received vaccination by 11 years of age, 2006–2012.
Source: National Immunization Survey-Teen, 2006–2012.
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Fig. 2. 
Hepatitis B vaccination coverage among adolescents aged 13–17 years, by race/ethnicity, 
United States, 2006–2012.
Source: National Immunization Survey-Teen 2006–2012.
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Fig. 3. 
Hepatitis B vaccination coverage among adolescents aged 13–17 years, by age group, 
United States, 2006–2012.
Source: National Immunization Survey-Teen 2006–2012.
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Table 2
Hepatitis B vaccination coverage and multivariable logistic regression analysis among adolescents 13–17 years 
in the United States, by demographic and access-to-care characteristics – NIS-Teen 2012.
Characteristic Hepatitis B vaccination coveragea Prevalence Difference (PD) (adjusted)
% (95% CI) p-Value† % (95% CI) p-Value‡
Total 92.8 (92.1–93.5)
Age (years)
 13–15c 93.3 (92.3–94.2) Ref.
 16–17 92.1 (90.9–93.1) 0.08 −1.0 (−2.5 to 0.4) 0.15
Sex
 Malec 92.7 (91.6–93.6)
 Female 93.0 (92.0–93.9) 0.63 0.3 (−1.0 to 1.6) 0.69
Race/ethnicityd
 Non-Hispanic Whitec 93.7 (92.9–94.3) Ref.
 Non-Hispanic Black 92.5 (90.1–94.4) 0.31 −0.2 (−2.8 to 2.4) 0.88
 Hispanic 91.1 (88.8–93.0) 0.02 −1.1 (−3.3 to 1.1) 0.33
 American Indian/Alaskan Native 94.1 (84.8–97.9) 0.88 0.7 (−5.1 to 6.5) 0.81
 Asian 92.0 (87.3–95.1) 0.41 −1.8 (−5.7 to 2.1) 0.37
 Other 92.1 (88.4–94.8) 0.35 −1.5 (−4.8 to 1.9) 0.39
Mother’s educational level
 <High Schoolc 90.8 (88.0–93.0) Ref.
 High School 91.9 (90.2–93.3) 0.48 −0.0 (−2.5 to 2.4) 0.98
 Some college or college graduate 92.1 (90.5–93.5) 0.38 −0.0 (−2.6 to 2.6) 0.98
 >College graduate 94.9 (94.1–95.6) <0.01 1.7 (−0.9 to 4.3) 0.20
Mother’s married status
 Marriedc 93.5 (92.7–94.2) Ref.
 Widowed/divorced/separated 91.9 (90.0–93.4) 0.08 −0.7 (−2.6 to 1.1) 0.43
 Never married 91.3 (87.8–93.8) 0.15 −1.1 (−4.3 to 2.1) 0.49
Mother’s age
 ≤34 yearsc 92.2 (89.6–94.2) Ref.
 35–44 years 92.7 (91.6–93.7) 0.66 0.2 (−2.0 to 2.4) 0.87
 ≥45 years 93.1 (92.0–94.0) 0.49 −1.1 (−3.6 to 1.5) 0.42
Immigration status
 Born in U.S.c 92.9 (92.1–93.6) Ref.
 Born outside U.S. 91.8 (88.6–94.2) −0.2 (−2.9 to 2.6) 0.91
Income to poverty ratioe
 <133%c 91.2 (89.7–92.5) Ref.
 133–<322% 92.4 (90.8–93.7) 0.25 0.7 (−1.3 to 2.8) 0.50
 322–<503% 93.6 (92.1–94.8) 0.02 0.8 (−1.7 to 3.4) 0.53
 >503% 95.9 (95.0–96.6) <0.01 3.2 (1.0–5.3) <0.01
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Characteristic Hepatitis B vaccination coveragea Prevalence Difference (PD) (adjusted)
% (95% CI) p-Value† % (95% CI) p-Value‡
Medical insurance
 Private Onlyc 94.2 (93.3–95.0) Ref.
 VFC Eligible-Medicaid/IHS/AIAN (All) 92.4 (91.2–93.4) 0.07 0.1 (−1.7 to 1.9) 0.89
 VFC Eligible-Uninsured 91.5 (88.2–93.9) 0.55 0.1 (−2.6 to 2.8) 0.94
 SCHIP (Public) 89.5 (81.1–94.4) 0.59 −2.7 (−8.6 to 3.2) 0.36
 Military 85.0 (79.2–89.4) 0.03 −4.9 (−10.8 to 1.0) 0.11
 Other 90.4 (79.5–95.8) 0.79 −2.2 (−10.2 to 5.7) 0.58
Physician contacts within past year
 Nonec 91.2 (89.3–92.7) Ref.
 1 94.1 (92.7–95.2) 0.01 1.6 (−0.4 to 3.5) 0.11
 2–3 92.4 (91.0–93.7) 0.08 −0.1 (−2.2 to 1.9) 0.89
 ≥4 93.2 (91.8–94.4) 0.34 0.4 (−1.6 to 2.4) 0.66
Well-child visit at age 11–12 years
 Yesc 96.0 (95.2–96.6) Ref.
 No 92.2 (90.8–93.5) <0.01 −3.3 (−5.1 to 1.6) <0.01
 Do not know 89.0 (87.2–90.5) <0.01 −4.8 (−6.5 to 3.0) <0.01
Number of vaccination provider
 1 92.9 (91.8–93.8) 0.71 1.0 (−1.3 to 3.2) 0.38
 2 92.6 (91.3–93.7) 0.64 −0.3 (−2.4 to 1.8) 0.79
 ≥3c 93.3 (91.5–94.8) Ref.
MSA
 Urban area 92.5 (91.3–93.6) 0.83 0.2 (−1.7 to 2.0) 0.86
 Suburban area 93.1 (92.0–94.1) 0.66 0.1 (−1.7 to 1.8) 0.94
 Rural areac 92.7 (91.3–93.9) Ref.
Regionb
 Northeast 95.3 (94.1–96.3) <0.01 3.4 (1.2 to 5.6) <0.01
 Midwest 91.6 (89.9–93.0) 0.61 0.5 (−2.0 to 2.9) 0.71
 South 93.7 (92.7–94.5) 0.01 2.3 (0.1 to 4.4) <0.01
 Westc 90.9 (88.7–92.7) Ref.
Facility type
 All private facilitiesc 93.7 (92.7–94.5) Ref.
 All public facilities 91.2 (88.6–93.3) 0.05 0.5 (−2.1 to 3.1) 0.71
 All hospital facilities 86.5 (83.3–89.2) <0.01 −4.6 (−7.6 to 1.6) <0.01
 All STD/school/teen clinics or other facilities 86.9 (77.4–92.8) 0.08 −2.9 (−9.1 to 3.4) 0.37
 Mixedf 95.8 (94.5–96.8) <0.01 3.7 (1.8 to 5.5) <0.01
 Otherg 73.8 (60.4–83.9) <0.01 −10.4 (−22.0 to 1.1) 0.08
†p Value by t test for comparisons within each variable with the indicated reference level.
‡p Value by t test for comparisons within each variable with the indicated reference level based on multivariable logistic model.
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a
Being fully immunized with Hepatitis B vaccine includes either received ≥3 doses of 0.5 ml Engerix® or Recombivax® or Comvax® vaccine or 
≥2 doses of 1.0 ml of Recombivax® vaccine.
bNortheast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; Midwest: 
Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; South: Alabama, 
Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South 
Carolina, Tennessee, Texas, Virginia, and West Virginia; West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New 
Mexico, Oregon, Utah, Washington, and Wyoming.
c
Reference level.
d
Race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, American Indian/Alaska Native, Asian, and other race (including multiple 
races).
eWe calculated the federal poverty level (PVL) by using the reported household income and the 2012 federal PVL thresholds defined by the U.S. 
Census Bureau.
f
Mixed indicates that the facility is identified to be in more than one of the facility categories such as private, public, hospital, STD/school/teen 
clinics.
g
Includes military, WIC clinics, and pharmacies.
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Table 3
Hepatitis B vaccination coverage of adolescents aged 13–17 years by state, NIS-Teen 2012.
Sample size Vaccination coveragea Vaccination coverage before 11 years 
of agea
Proportion vaccinated at or 
after 11 years of agea,b
N % (95% CI) % (95% CI)
National 19,199 92.8 (92.1–93.5) 90.6 (89.8–91.4) 23.4
Alabama 317 96.4 (93.8–97.9) 95.1 (91.9–97.1) 26.5
Alaska 340 91.1 (87.2–93.9) 88.8 (84.5–92.1) 20.5
Arizona 360 84.5 (78.2–89.2) 83.5 (77.2–88.3) 6.1
Arkansas 322 92.6 (88.5–95.3) 90.4 (85.6–93.7) 22.9
California 430 92.4 (88.1–95.2) 90.3 (85.4–93.7) 21.6
Colorado 311 96.4 (93.7–98.0) 95.5 (92.3–97.4) 20.0
Connecticut 323 95.7 (92.0–97.8) 94.5 (90.4–96.9) 21.8
Delaware 341 94.8 (90.9–97.0) 91.7 (86.7–94.9) 37.3
District of Columbia 342 92.7 (86.8–96.1) 89.9 (83.4–94.0) 27.7
Florida 325 98.7 (96.5–99.5) 94.0 (87.1–97.3) 78.3
Georgiac 328 97.1 (92.8–98.9) 94.7 (88.8–97.6) 45.3
Hawaii 342 92.3 (88.0–95.2) 90.2 (85.1–93.7) 21.4
Idaho 357 91.1 (86.8–94.0) 88.7 (83.7–92.4) 21.2
Illinois 632 90.7 (85.6–94.0) 89.2 (84.0–92.9) 13.9
Indiana 341 94.9 (90.5–97.3) 93.9 (89.1–96.6) 16.4
Iowac 325 93.8 (89.4–96.4) 92.0 (86.7–95.3) 22.5
Kansas 340 91.3 (85.9–94.7) 88.4 (82.8–92.3) 25.0
Kentucky 333 95.0 (91.3–97.1) 95.0 (91.3–97.1) 0.0
Louisiana 370 95.6 (92.1–97.6) 94.1 (90.2–96.5) 25.4
Mainec 319 93.6 (89.7–96.1) 90.8 (86.3–93.9) 30.4
Maryland 325 94.5 (89.9–97.1) 93.5 (88.9–96.2) 15.4
Massachusetts 347 95.9 (91.7–98.0) 92.5 (87.8–95.5) 45.3
Michigan 368 93.3 (88.6–96.2) 92.5 (87.8–95.5) 10.7
Minnesota 322 94.1 (90.4–96.5) 91.5 (86.6–94.7) 30.6
Mississippic 321 93.5 (87.3–96.8) 92.9 (86.8–96.3) 8.5
Missouri 292 87.9 (82.1–92.0) 85.9 (79.3–90.7) 14.2
Montanac 325 89.8 (85.4–92.9) 89.1 (84.7–92.3) 6.4
Nebraska 328 90.0 (84.5–93.7) 88.6 (83.1–92.5) 12.3
Nevadac 329 90.5 (85.8–93.8) 87.4 (81.3–91.7) 24.6
New Hampshire 278 97.3 (94.6–98.7) 96.9 (94.0–98.4) 12.9
New Jersey 330 96.9 (93.4–98.6) 94.7 (90.1–97.3) 41.5
New Mexico 331 89.9 (85.3–93.3) 85.5 (79.4–90.0) 30.3
New York 627 94.6 (92.0–96.4) 91.4 (88.5–93.7) 37.2
North Carolina 347 95.6 (92.0–97.6) 92.9 (88.1–95.9) 38.0
North Dakotac 324 91.2 (85.1–95.0) 88.8 (82.1–93.1) 21.4
Vaccine. Author manuscript; available in PMC 2018 February 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lu et al. Page 23
Sample size Vaccination coveragea Vaccination coverage before 11 years 
of agea
Proportion vaccinated at or 
after 11 years of agea,b
N % (95% CI) % (95% CI)
Ohio 327 88.4 (81.9–92.8) 88.4 (81.9–92.8) 0.0
Oklahoma 322 95.0 (91.9–96.9) 93.3 (89.6–95.7) 25.4
Oregon 381 92.7 (88.9–95.2) 91.5 (87.7–94.3) 14.1
Pennsylvania 741 94.8 (91.7–96.8) 93.1 (89.5–95.5) 24.6
Rhode Island 327 94.3 (89.5–97.0) 91.5 (86.3–94.8) 32.9
South Carolina 310 92.9 (88.1–95.9) 92.8 (88.1–95.8) 1.4
South Dakotac 298 90.3 (85.4–93.6) 88.3 (83.1–92.1) 17.1
Tennessee 331 96.2 (93.2–97.9) 94.3 (90.0–96.8) 33.3
Texas 1594 87.6 (84.6–90.1) 84.1 (80.8–86.9) 22.0
Utahc 345 85.5 (79.6–89.9) 84.8 (78.8–89.3) 4.6
Vermont 322 93.4 (88.7–96.3) 90.8 (86.0–94.1) 28.3
Virginia 334 92.7 (88.1–95.5) 90.3 (84.6–94.0) 24.7
Washington 353 86.5 (80.2–91.0) 83.3 (76.5–88.3) 19.2
West Virginiac 282 84.4 (77.6–89.4) 81.1 (73.6–86.9) 17.5
Wisconsin 307 94.1 (91.0–96.2) 91.2 (86.5–94.3) 33.0
Wyoming 333 94.5 (91.0–96.7) 93.7 (89.9–96.2) 12.7
Median 93.3 91.3 24.6
Range 84.4–98.7 81.1–96.9 0.0–78.3
a
Being fully immunized with Hepatitis B vaccine includes either received ≥3 doses of 0.5 ml Engerix® or Recombivax® vaccine or ≥2 doses of 
1.0 ml of Recombivax® vaccine.
b
Proportion vaccinated after turning 11 years of age among those not fully vaccinated against HepB vaccination before 11 years of age.
c
Indicate that states without middle school HepB vaccination requirement.
Vaccine. Author manuscript; available in PMC 2018 February 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lu et al. Page 24
Ta
bl
e 
4
Cu
m
ul
at
iv
e 
pe
rc
en
t r
ec
ei
v
in
g 
fu
ll 
H
ep
at
iti
s B
 v
ac
ci
na
tio
na
 
by
 a
ge
 a
nd
 b
irt
h 
co
ho
rt,
 a
do
le
sc
en
ts 
ag
ed
 1
3–
17
 y
ea
rs
, N
IS
-T
ee
n
 2
00
6–
20
12
.
Bi
rt
h 
co
ho
rt
A
ge
 in
 y
ea
rs
<
1
<
2
<
3
<
4
<
5
<
6
<
7
<
8
<
9
<
10
<
11
<
12
<
13
<
14
<
15
<
16
<
17
19
89
0.
8
0.
8
1.
0
2.
8
6.
4
11
.6
13
.8
18
.2
25
.1
31
.3
39
.8
51
.9
68
.5
73
.4
75
.8
76
.9
78
.1
19
90
1.
5
2.
2
5.
5
9.
5
12
.6
17
.5
21
.0
26
.1
32
.3
39
.7
49
.7
59
.1
70
.9
75
.5
77
.6
79
.3
80
.5
19
91
1.
2
7.
1
12
.1
14
.5
19
.6
27
.7
35
.6
41
.0
45
.9
51
.9
57
.1
64
.4
73
.3
77
.3
79
.3
81
.6
82
.6
19
92
23
.0
38
.0
42
.5
46
.0
53
.1
63
.4
68
.1
70
.6
72
.9
74
.9
77
.3
80
.9
83
.9
85
.0
86
.1
86
.8
87
.6
19
93
52
.3
66
.7
70
.4
73
.6
76
.9
81
.5
83
.1
84
.0
85
.0
85
.4
86
.4
87
.6
88
.4
89
.1
89
.7
90
.3
90
.8
19
94
61
.3
74
.6
78
.4
80
.9
83
.1
85
.5
86
.6
87
.2
87
.8
88
.3
88
.9
89
.4
90
.2
90
.6
91
.0
91
.7
93
.0
19
95
66
.7
79
.2
81
.7
83
.6
85
.5
87
.6
88
.6
89
.0
89
.3
4
89
.9
90
.5
91
.0
91
.3
91
.8
92
.1
92
.7
93
.1
19
96
71
.3
82
.4
85
.1
86
.6
88
.0
89
.3
89
.9
90
.1
90
.3
90
.7
91
.1
91
.5
92
.1
92
.6
92
.8
93
.3
19
97
71
.4
83
.3
85
.3
86
.9
88
.1
89
.5
90
.5
90
.9
91
.3
91
.7
92
.5
93
.1
93
.6
93
.8
94
.2
19
98
70
.7
83
.3
85
.5
87
.0
88
.8
90
.0
90
.5
91
.1
91
.4
91
.6
92
.4
92
.9
93
.2
93
.5
19
99
56
.0
81
.7
85
.1
87
.3
89
.0
90
.1
90
.4
90
.8
91
.0
91
.1
91
.5
91
.8
92
.4
a B
ei
ng
 fu
lly
 im
m
un
iz
ed
 w
ith
 H
ep
at
iti
s B
 v
ac
ci
ne
 in
cl
ud
es
 e
ith
er
 re
ce
iv
ed
 ≥
3 
do
se
s o
f 0
.5
 m
l E
ng
er
ix
®
 
o
r 
R
ec
om
bi
v
ax
®
 
v
ac
ci
ne
 o
r ≥
2 
do
se
s o
f 1
.0
 m
l o
f R
ec
om
bi
v
ax
®
 
v
ac
ci
ne
. T
he
 st
an
da
rd
 e
rro
rs
 fo
r t
he
 
es
tim
at
es
 ra
ng
ed
 fr
om
 0
.2
 to
 2
.6
.
Vaccine. Author manuscript; available in PMC 2018 February 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lu et al. Page 25
Ta
bl
e 
5
Cu
m
ul
at
iv
e 
pe
rc
en
t r
ec
ei
v
in
g 
fu
ll 
H
ep
at
iti
s B
 a
do
le
sc
en
t c
at
ch
-u
p 
va
cc
in
at
io
na
 
by
 a
ge
 a
nd
 b
irt
h 
co
ho
rt,
 a
m
on
g 
ad
ol
es
ce
nt
s a
ge
d 
13
–1
7 
ye
ar
s w
ho
 h
ad
 n
ot
 
re
ce
iv
ed
 fu
ll 
H
ep
B 
va
cc
in
at
io
n 
be
fo
re
 a
ge
 1
1 
ye
ar
s, 
N
IS
-T
ee
n
 2
00
6–
20
12
.
Bi
rt
h 
co
ho
rt
In
di
ca
te
 th
at
 v
a
cc
in
at
io
ns
 a
re
 c
o
u
n
te
d 
if 
re
ce
iv
ed
 o
n 
or
 a
fte
r 
th
e 
11
th
 b
ir
th
da
ya
<
12
<
13
<
14
<
15
<
16
<
17
19
89
20
.5
48
.0
56
.1
60
.1
61
.9
63
.8
19
90
18
.7
42
.2
51
.4
55
.5
58
.9
61
.3
19
91
17
.1
37
.8
47
.3
51
.8
57
.1
59
.6
19
92
15
.9
29
.3
33
.9
39
.0
42
.1
45
.3
19
93
8.
6
14
.8
19
.7
23
.8
28
.5
32
.2
19
94
4.
8
11
.7
15
.7
19
.5
25
.4
37
.2
19
95
5.
8
8.
8
13
.6
16
.8
23
.1
27
.4
19
96
4.
0
10
.7
16
.4
19
.1
24
.1
19
97
7.
9
14
.3
17
.6
22
.8
19
98
6.
9
10
.7
15
.0
19
99
4.
9
12
.3
a B
ei
ng
 fu
lly
 im
m
un
iz
ed
 w
ith
 H
ep
at
iti
s B
 v
ac
ci
ne
 in
cl
ud
es
 e
ith
er
 re
ce
iv
ed
 ≥
3 
do
se
s o
f 0
.5
 m
l E
ng
er
ix
®
 
o
r 
R
ec
om
bi
v
ax
®
 
v
ac
ci
ne
 o
r ≥
2 
do
se
s o
f 1
.0
 m
l o
f R
ec
om
bi
v
ax
®
 
v
ac
ci
ne
. T
he
 st
an
da
rd
 e
rro
rs
 fo
r t
he
 
es
tim
at
es
 ra
ng
ed
 fr
om
 0
.8
 to
 4
.6
.
Vaccine. Author manuscript; available in PMC 2018 February 12.
